Lung Cancer – Non-Small Cell

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer (01-8-2018)

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free... Continue Reading

The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer (12-6-2017)

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy – if targeted therapy is not an option immunotherapy... Continue Reading

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer (11-13-2017)

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December... Continue Reading

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain (09-21-2017)

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC)... Continue Reading

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation (06-26-2017)

The U.S. Food and Drug Administration granted regular approvals to Tafinlar® (dabrafenib) and Mekinist® (trametinib) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by... Continue Reading

Alecensa Superior to Xalkori in Treatment of Lung Cancer (06-12-2017)

Alecensa (alectinib) halted the spread of lung cancer for a median of 15 months longer than treatment with rival Xalkori (crizotinib) with fewer side effects, according to trial results presented at the 2017 American Society of Clinical Oncology annual... Continue Reading

Radiation Therapy can Enhance Effectiveness of Immunotherapy in People With Advanced Lung Cancer (06-2-2017)

UCLA RESEARCH ALERT FINDINGS A new study by UCLA scientists has found that the breakthrough immunotherapy drug Keytruda (pembrolizumb)  can be more effective in improving survival in people with non-small cell lung cancer (NSCLC) if they have previously... Continue Reading

Imfinzi Improves Outcomes for Patients With Stage III Non Small Cell Lung Cancer (05-30-2017)

Positive results for the PACIFIC clinical trial evaluating the novel precision medicine, Imfinzi (durvalumab) as sequential treatment in patients with Stage III non-small cell lung cancer (NSCLC) who had not progressed following standard platinum-based... Continue Reading

Tagrisso Approved for Treatment of Certain Lung Cancers (04-18-2017)

The U.S. Food and Drug Administration granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an... Continue Reading

Opdivo Appears to Significantly Improve Five-Year Survival Rates in Advanced Lung Cancer (04-13-2017)

Treatment with the immune checkpoint inhibitor Opdivo (nivolumab) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data presented here at the AACR Annual... Continue Reading

Next Page »